Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Anteris Technologies Global Corp. (AVR : NSDQ)

• Company Description    Anteris Technologies Global Corp. is involved in designing, developing and commercializing cutting-edge medical devices to restore healthy heart function. The company's lead product includes DurAVR(R). Anteris Technologies Global Corp. is based in BRISBANE, Australia. Number of Employees: 136

• Price / Volume Information    Yesterday's Closing Price: $4.99 Daily Weekly Monthly 20 Day Moving Average: 196,320 shares Shares Outstanding: 41.20 (millions) Market Capitalization: $205.58 (millions) Beta: 52 Week High: $8.79 52 Week Low: $2.34 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 9.91% 10.10% 12 Week 2.05% 0.40% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL TOOWONG TOWER LEVEL 3 SUITE 302 9 SHERWOOD ROAD - Toowong,C3 4066 AUS ph: 61-7-3152-3200 fax: - None https://anteristech.com/home.html

• General Corporate Information    Officers Wayne Paterson - Chief Executive Officer and Vice Chairman John Seaberg - Chairman of the Board of Directors David St Denis - President and Director Matthew McDonnell - Chief Financial Officer Stephen Denaro - Director Peer Information Anteris Technologies Global Corp. (ABMD) Anteris Technologies Global Corp. (DMDS) Anteris Technologies Global Corp. (CPWY.) Anteris Technologies Global Corp. (EQUR) Anteris Technologies Global Corp. (ECIA) Anteris Technologies Global Corp. (FMS) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED INSTRUMENTS Sector: Medical CUSIP: 03675P102 SIC: 3842 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/11/26 Share - Related Items Shares Outstanding: 41.20 Most Recent Split Date: (:1) Beta: Market Capitalization: $205.58 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.47 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 57.06 Price/Cash Flow: - Price / Sales: 96.11 EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -6.90% Sales Growth vs. Year Ago Period: -44.21% vs. Previous Quarter: -30.58% ROE 12/31/25 - - 09/30/25 - -252.71 06/30/25 - -257.86 ROA 12/31/25 - - 09/30/25 - -169.61 06/30/25 - -186.64 Current Ratio 12/31/25 - - 09/30/25 - 0.84 06/30/25 - 2.41 Quick Ratio 12/31/25 - - 09/30/25 - 0.80 06/30/25 - 2.38 Operating Margin 12/31/25 - - 09/30/25 - -3,933.75 06/30/25 - -3,376.08 Net Margin 12/31/25 - - 09/30/25 - -3,944.93 06/30/25 - -3,385.72 Pre-Tax Margin 12/31/25 - - 09/30/25 - -3,945.91 06/30/25 - -3,387.98 Book Value 12/31/25 - - 09/30/25 - 0.09 06/30/25 - 0.67 Inventory Turnover 12/31/25 - - 09/30/25 - 1.56 06/30/25 - 3.04 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.01 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.77 06/30/25 - 0.12

Powered by Zacks Investment Research ©